StockpollyBeta
Get App
Popularity #1,706
AGEN · NASDAQ · Biotechnology

Agenus (AGEN)

Develops investigational BOT+BAL antibodies for colorectal cancer and selected tumors.

$8.45
vs last close−0.25 (−2.92%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue248428242527242630343435
Cost of revenue52673374134222724810
Gross profit−271725−13−16−72−16273335
192157171519161511121823
Research & development51044370342227001215
1921131717211616111278
Selling & marketing00−3000000000
General & administrative1921171717211616111278
Other expenses−5100−37−2−36−22−2700−10
Operating income−46−4−33−30−32−26−13−17−5141511
−18−44−31−25−36−21−13−1368−2524−12
Interest income000000000000
Interest expense194429323621131313161515
Other non-operating income001−70000−829−39−3
Income before tax−65−49−63−55−67−47−26−3064−1139−1
Net income from continuing operations−65−49−63−55−67−47−26−3064−1139−1
Net income−62−46−62−53−66−46−25−2864−1139−1
EPS, basic−$3.29−$2.48−$3.11−$2.52−$3.08−$2.04−$1.03−$1.00$2.00−$0.30$1.03−$0.01
EPS, diluted−$3.29−$2.48−$3.11−$2.52−$3.08−$2.04−$1.03−$1.00$1.94−$0.30$1.02−$0.01
Weighted average shares, basic191920212223242832353841
Weighted average shares, diluted191920212223242833353841
EBITDA−431−31−20−28−23−10−148065415
Depreciation & amortization353333333111
EBIT−46−4−34−23−31−26−14−177755415